Investor Ideas #Potcasts
602, #Cannabis News and #Stocks on the Move; (TSX: $VLNS.TO) (OTCQX: $VLNCF),
(TSX: $HEXO.TO) (NASDAQ: HEXO), (NEO: MEDI), (CSE: $BHSC.C)
Delta, Kelowna, BC, September 1, 2021 (Investorideas.com
Newswire) http://www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s
podcast edition of cannabis
news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/090121-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/09011VLNS-HEXO-MEDI-BHSC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
BioHarvest
Sciences Inc. (CSE: BHSC) announced that it has successfully scaled its
Cannabis cells with trichomes production by a factor of 250x and it is now
growing Cannabis in medium-scale bioreactors, paving the way for its next
scale-up milestone, where it will reach industrial-scale production. The next
milestone, combined with the drying and measurement standards being
concurrently developed, would constitute the successful completion of the
Company's Cannabis development program.
Moving to the medium-scale
bioreactors stage is not only a critical milestone in the scale-up and the
proof of the capability of the BioFarming technology to produce Cannabis
biomass, but is also an integral part of the industrial process development
itself. The next milestone of the development program is growing Cannabis
trichomes in industrial size bioreactors.
"The R&D methodology and
relentless efforts are paying off," said Dr. Yochi Hagay, CTO, and added,
"We are happy to have reached such a critical milestone. The recently
announced and proprietary development of the Amalgamated Trichomes Coral
Structure (ATCS) has certainly enabled this scale-up progress. As described
before, ATCS protects the Trichomes during the growth phase against the shear
forces generated by the media fluid motion. Such motion is exacerbated as you
increase the size of the bioreactor, and I am confident that ATCS will sustain
the forces in the next size of bioreactors, which is the final industrial-scale
step. I look forward to announcing the completion of the whole program
soon."
The CEO, Ilan Sobel, said, "Our
industry-leading plant cell biology team is on track to deliver on one of the
most challenging plant biological missions of growing cells of Cannabis
Trichomes in liquid media at an industrial scale. Completing this mission will
pave the way to the commercialization of BioFarming based Cannabis and Hemp
products, marking a major turning point for the mainstream adoption of Cannabis
by the global food and health sectors. The ability to economically and
sustainably produce consistent, clean and pure whole spectrum Cannabis is
nothing short of a revolution for the industry."
Eitan Popper, Chairman of BHSC's
board of advisors and former President and Co-Founder of MedReleaf, stated,
"BHSC's R&D team is making meaningful progress every month in the
commercial scale-up of their Cannabis production. It is important to note that
the most challenging part of the scale-up process is the transition from
lab/bench scale to small-scale bioreactors, and then to medium-scale
bioreactors. We are eagerly looking forward to the next Cannabis milestone
announcement, as we know that it will be meaningful."
KetamineOne
Capital Limited (NEO: MEDI) (OTC: KONEF), a company focused on
consolidating medical clinics and becoming a North American leader in mental
health treatments, announced that it has reached a commercial agreement with Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) for Cognetivity’s Integrated
Cognitive Assessment to be deployed in Ketamine One’s clinics across North
America. The Company and Cognetivity have also entered into a non-binding
letter of intent to collaborate on mental health assessments and plan on
conducting clinical trials within Ketamine One’s network of clinics.
Cognetivity is a technology company
that has created a cognitive testing platform for use in medical, commercial
and consumer environments. Pursuant to the terms of the Agreement, Ketamine One
plans to deploy Cognetivity’s ICA across its network clinics to enable the
long-term monitoring of cognitive performance in patients with
treatment-resistant depression and post-traumatic stress disorder (“PTSD”). The
ICA offers numerous benefits to clinicians, particularly in comparison to
traditional, pen-and-paper-based tests. A computerized assessment that takes
five minutes, the ICA is user-friendly and exhibits no learning effect upon
repeat testing, making it perfectly suited to long-term monitoring.
The ICA is also highly sensitive to
small changes in cognitive performance and, owing to its computerized nature,
is capable of supporting remote, self-administered testing. Assessing
individuals’ cognition over the course of their treatment will enable the
measurement of treatment efficacy, while empowering patients to take charge of
their wellbeing and providing clinicians with additional data to refine
treatment and improve outcomes.
In addition to the ICA’s deployment
in Ketamine One’s clinics, the LOI will see Cognetivity and Ketamine One
collaborate on developing and validating next-generation mental health
assessment tools to improve the lives of sufferers. The Company believes that
Cognetivity offers a unique and technologically advanced assessment tool that
can help standardize in clinic procedures and offer a powerful analytical
element to Ketamine One’s digital therapeutic platform.
It is widely accepted that there is
vast potential for improvement in the treatment of such conditions. According
to the WHO, mental health disorders account for 28% of the global burden of
disability-adjusted life years among non-communicable diseases – more than
cardiovascular disease or cancer. Every year, more than 12 billion working days
are lost due to mental health conditions, costing the global economy US$16
trillion in economic output between 2011 and 2030. The estimated addressable
market size for anxiety disorder and depression treatments is US$238 billion.
HEXO
Corp.
(TSX: HEXO) (NASDAQ: HEXO) and 48North Cannabis Corp. announced that they have completed the
previously announced arrangement, pursuant to which HEXO has acquired all of
the issued and outstanding common shares of 48North by way of a court-approved
plan of arrangement under the Canada
Business Corporations Act
.
Under the terms of the Arrangement,
each former shareholder of 48North is now entitled to receive 0.02366 of a
common share in the capital of HEXO for each 48North Share held immediately
prior to the completion of the Arrangement. It is anticipated that the 48North
Shares will be de-listed from the TSX Venture Exchange as of the close of
trading on or about September 2, 2021.
In order to receive the
Consideration, registered holders of 48North Shares will be required to deposit
their share certificate(s) representing 48North Shares, together with a duly
completed letter of transmittal, with TSX Trust Company, the depositary under
the Arrangement. Shareholders whose 48North Shares are registered in the name
of a broker, dealer, bank, trust company or other nominee should contact their
nominee regarding the receipt of the Consideration.
Further information about the
Arrangement is set forth in the materials prepared by 48North in respect of the
special meeting of 48North Shareholders held on August 17, 2021 (the
"Meeting"), which were mailed to 48North Shareholders and filed under
48North's profile on the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.
The
Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of
cannabis products, announced that it has completed a transaction
to acquire Verse Cannabis including
all of the Verse intellectual property. This acquisition, and Valens' recently
announced agreement to acquire Citizen Stash Cannabis Corp., positions Valens
as a top tier cannabis licensed producer in the Canadian industry by total
provincial listings and market share.
Since launching in August 2020,
Verse has emerged as a leading cannabis brand with a wide-ranging portfolio
that spans all major product categories. Verse has been a pioneer in the value
segment starting with its Tropic Lemon 510 thread vape cartridges (including
one of the first 1.0g cartridges on the market) and continuing with the recent
launch of BC God Bud 28g offering. Today, Verse boasts a number of innovative
products in its portfolio such as the Sour Medley and Baked Apple Soft Chews,
Double Chocolate Brownie, THC and CBD SoRSE-based drops and the Rapid Tropical
Rush beverage to name a few. With over 90 provincial listings across 7 provinces
and territories today, Verse offers a wide selection of high-quality products
providing consumers an array of cannabis consumption experiences without the
uncomfortably high price point. Valens aims to leverage Verse products as its
lead value-focused offering within its brand portfolio.
Tyler Robson, Chief Executive
Officer and Chair of the Board of The Valens Company, said, "The
acquisitions of Verse and Citizen Stash were motivated by an underlying desire
to become an ally to both our customers and consumers. We believe in creating
best-in-class products that consumers deserve in the right way, without ever
cutting corners. Whether it's medical or recreational, local or international,
third-party owned brands or Valens owned brands, we're pursuing purity in
extraction, formulation, product development and testing to bring the benefits
of cannabis to the world. The expanded platform we have built at Valens is now
positioned to better serve current and future customers and consumers through
unique product offerings at attractive price points while maximizing
shareholder value through Valens branded products."
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on
iTunes ( Apple Podcasts) , Audible ,
Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Podcasts and most audio platforms
available.
Potcasts is now
a certified word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com -
News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news, third party stock research , guest posts and
original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor
ideas in cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy, gaming and more. Investor Idea’s original branded content includes
podcasts and columns : Crypto Corner , Play
by Play sports and stock news , Investor Ideas Potcasts
Cannabis News and Stocks on the Move podcast ,
Cleantech
and Climate Change , Exploring
Mining , Betting
on Gaming Stocks Podcast and the AI
Eye Podcast.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our
other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for
iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment